HWP
RLAY icon

Highline Wealth Partners’s Relay Therapeutics RLAY Stock Holding History

Highline Wealth Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,000
Closed -$17.3K – 1123
2025
Q2 		$17.3K Buy
+5,000
New +$14.9K 0.01% 246

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Highline Wealth Partners's RLAY Position: Q3 2025 in Review

Highline Wealth Partners sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 5,000 shares — an estimated $17.3K sold.

Highline Wealth Partners first reported a position in RLAY in Q2 2025 and held it in 1 quarter. The position peaked at $17.3K in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • Highline Wealth Partners reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Highline Wealth Partners sold 5,000 Relay Therapeutics shares in Q3 2025, an estimated $17.3K.
  • Highline Wealth Partners first reported a position in Relay Therapeutics in Q2 2025 and held it in 1 quarter.
  • Highline Wealth Partners's Relay Therapeutics position peaked at $17.3K in Q2 2025.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on Highline Wealth Partners's 13F filing for Q3 2025, filed 14 Oct 2025.